The first clinical study of Redsiway's treatment, New Crown, has been published

As of 6:15 a.m. Beijing time on April 13, there were more than 1.84 million confirmed cases of new crown pneumonia worldwide, including more than 550,000 confirmed cases and more than 21,000 deaths in the United States, the largest number of confirmed cases in the world, according to Johns Hopkins University.Under the outbreak, the world is trying to find effective drugs and medicines. Among them, Gilead Sciences of the United States in the study of the drug Redsiway has been high hopes, but also regarded as "the hope of the people." On April 11, the New England Journal of Medicine published Remdesivir's first clinical results. The results of the trial, which treated patients with severe neo-coronary pneumonia, showed that 68 percent of the 53 patients with severe and critical COVID-19 had symptoms relieved and had a mortality rate of 13 percent.It is worth noting that the study was conducted in the context of sympathetic drug use, so there was no control group that could not evaluate the direct relationship between Redsyves and the improvement of symptoms in patients. Although the results of the trial show some positive signals, there are limitations to the data on sympathetic drug use, so it needs to be viewed with caution.In addition to the highly-expected Redsivir, research and development and trials of other drugs are also under way. In addition, scientists are actively deciphering the key "passwords" of the new coronavirus structure in an attempt to speed up the development of new coronary pneumonia drugs.Recently, Rao Zi and a team of academicians from Shanghai University of Science and Technology took the lead in successfully analyzing the results of the research results on the three-dimensional spatial structure of the new coronavirus "RdRp(RNA-dependent RNA polymerase)-nsp7-nsp8 complex" near-atomic resolution. The study revealed the structural characteristics of the core "engine" of the viral genetic material transcription replication machine, which laid an important foundation for the development of drugs for neo-crown pneumonia.The findings were published in the journal Science under the title "Structure of the RNA-dependent RNA polymerase from COVID-19 Virus".We know that after invading the host cells, the new coronavirus begins to replicate in large numbers, with the process of transcription and replication of the genetic material RNA genome at its core. Transcription of genetic material will eventually be translated to form the structure of the newborn virus to form a protein, and its replication will form the RNA genome of the newborn virus. Viral RNA-dependent RNA polymerases (RNA-dependent RNA polymerases, RdRp), also known as non-structural proteins No. 12 (non-structural protein 12, nsp12), are able to assemble with several other unstructic proteins to form an efficient RNA synthesis "machine" to complete both processes. RNA polymerase, as the core component of this transcription replication machine, is one of the most important antiviral drug targets, and its destruction of its function is expected to prevent the replication of viruses and ultimately achieve therapeutic goals.In this study, the analyzed composite structure showed that the RNA polymerase of the new coronavirus had conservative characteristics of other viral RNA polymerases and contained niran (Nidovirus) Niran (Nidovirus RdRp-associatednucleotyltransferase), while the viral RNA polymerase and the virus's non-structural proteins nsp7 and nsp8 formed the core unit of the transcription replication machine.Excitingly, for the first time, researchers have also discovered a unique "β card" domain on the N side of the RNA polymerase of the new coronavirus, which provides new clues to the biological function of the new coronavirus RNA polymerase. Through an in-depth analysis of the atomic resolution structure, the team also discovered the key amino acid residues of the function of the new coronavirus RNA polymerase, and compared it with the structure of the Sofosbuvir effect molecule of the hepatitis C virus polymerase ns5b-Sofosbuvir effect, and proposed the possible action mode of the effect molecules of Redsivir and Fabiravir (i.e., the final product after metabolism) inhibiting the new coronavirus RNA polymerase.This study for the first time finely depicts the internal structure of the new coronavirus "RdRp-nsp7-nsp8" transcription and replication machine, and provides a reasonable mechanism explanation for how the effect molecules of candidate drugs such as Redsivir and Fabiravir accurately target the viral RNA synthesis and thus exert the physioactive activity, which lays an important theoretical foundation for further study of the molecular mechanism of the new coronavirus replication and opens up a new way to develop special effects drugs against the new coronary pneumonia.
(Biological Exploration)